Description
Alnylam Pharmaceuticals’ $1.3 Billion Revenue Surge: Is AMVUTTRA’s Growth Just Beginning?
Alnylam Pharmaceuticals, Inc. reported third-quarter 2026 results characterized by strong top-line growth in product revenues alongside ongoing challenges in translating commercial expansion efforts into accelerated demand. Total global net product revenues rose 52% year over year to approximately $1.3 billion, driven primarily by the transthyretin (TTR) franchise with products such as AMVUTTRA and ATTR cardiomyopathy treatments. The TTR category showed nearly 60% growth year over year, reflecting the expanding but still incomplete adoption of AMVUTTRA, which now accounts for about 24% of total TTR prescriptions despite only one-third of prescribers having initiated treatment, indicating room for growth in market penetration. Commercially, the company expanded its sales force to enhance prescriber engagement, resulting in increased interactions and a growing prescriber base exceeding 2,000 unique physicians.



